David R. Gandara, M.D. for UC Davis Health

Dr. David R. Gandara

Claim this profile

University of California Davis Comprehensive Cancer Center

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
22 drugs studied

Area of expertise

1Lung Cancer
Global Leader
David R. Gandara has run 11 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
David R. Gandara has run 10 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Affiliated Hospitals

Image of trial facility.
University Of California Davis Comprehensive Cancer Center
Image of trial facility.
Fremont - Rideout Cancer Center

Clinical Trials David R. Gandara is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Tepotinib + Ramucirumab

for Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria

More about David R. Gandara

Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments David R. Gandara has experience with
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Ramucirumab
  • Gemcitabine Hydrochloride
  • Pemetrexed Disodium

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does David R. Gandara specialize in?
Is David R. Gandara currently recruiting for clinical trials?
Are there any treatments that David R. Gandara has studied deeply?
What is the best way to schedule an appointment with David R. Gandara?
What is the office address of David R. Gandara?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security